AMICAR Drug Patent Profile

Which patents cover Amicar, and when can generic versions of Amicar launch?

Amicar is a drug marketed by Epic Pharma Llc and Hikma and is included in three NDAs.

The generic ingredient in AMICAR is aminocaproic acid. There are six drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the aminocaproic acid profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Amicar

A generic version of AMICAR was approved as aminocaproic acid by LUITPOLD on December 1^st, 1987.

Summary for AMICAR

US Patents:	0
Applicants:	2
NDAs:	3

US Patents and Regulatory Information for AMICAR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Epic Pharma Llc	AMICAR	aminocaproic acid	INJECTABLE;INJECTION	015229-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Hikma	AMICAR	aminocaproic acid	TABLET;ORAL	015197-001	Approved Prior to Jan 1, 1982	AB	RX	Yes	No
Hikma	AMICAR	aminocaproic acid	SOLUTION;ORAL	015230-002	Approved Prior to Jan 1, 1982	AA	RX	Yes	No
Hikma	AMICAR	aminocaproic acid	TABLET;ORAL	015197-002	Jun 24, 2004	AB	RX	Yes	No

AMICAR (Aminocaproic Acid) Investment Analysis

Last updated: February 19, 2026

AMICAR, an antifibrinolytic agent, presents a stable, established market for treatment of excessive bleeding. Its utility in surgical settings and specific bleeding disorders forms the core of its value proposition. The drug’s long history of clinical use and a well-understood safety profile contribute to its consistent demand.

What is AMICAR's Mechanism of Action and Therapeutic Use?

AMICAR, also known by its generic name aminocaproic acid, is a synthetic antifibrinolytic agent. It functions by competitively inhibiting the activation of plasminogen to plasmin, an enzyme responsible for degrading fibrin clots. By preventing plasmin formation, AMICAR enhances hemostasis and reduces bleeding.

Primary therapeutic uses for AMICAR include:

• Control of Excessive Bleeding: AMICAR is indicated for the treatment of patients with hyperfibrinolysis, a condition where the body breaks down blood clots too rapidly. This is particularly relevant in situations such as:
  • Surgical Procedures: It is used to reduce or prevent bleeding during and after major surgeries, including cardiac, thoracic, and gynecological procedures [1].
  • Trauma: AMICAR can be administered in cases of severe traumatic injury to mitigate life-threatening hemorrhage.
  • Certain Bleeding Disorders: It is employed in the management of bleeding associated with conditions like hemophilia and von Willebrand disease, where fibrinolysis plays a significant role in the bleeding diathesis [2].
• Management of Hematuria: AMICAR is effective in treating macroscopic hematuria due to various causes, such as bladder cancer, prostatic surgery, or after prostatic surgery [3].

What is the Market Size and Growth Potential for AMICAR?

The market for AMICAR is mature, characterized by consistent demand driven by its established efficacy and broad application in critical care and surgical settings. The global antifibrinolytic market, which AMICAR is a part of, is estimated to have been valued at approximately USD 1.1 billion in 2022 [4]. While specific figures for AMICAR alone are not publicly dissected, its long-standing presence suggests a significant, albeit not rapidly expanding, share of this market.

Growth in the AMICAR market is primarily influenced by:

• Surgical Volume: An aging global population and advancements in surgical techniques lead to a steady increase in the number of surgical procedures, directly correlating with AMICAR demand. The global surgical procedures market is projected to grow at a CAGR of 6.5% from 2023 to 2030 [5].
• Trauma Care Advancements: Increased focus on trauma response and critical care protocols worldwide supports the continued use of AMICAR in emergency settings.
• Generic Competition: AMICAR is widely available as a generic drug, leading to price competition and making it an accessible treatment option. This accessibility sustains its market presence.
• Emerging Indications (Limited): While major new indications are unlikely given its established mechanism, research into niche applications or specific patient populations experiencing hyperfibrinolytic bleeding could present minor growth opportunities.

The overall market growth is projected to be modest, likely in the low single digits annually, reflecting its status as a well-established therapeutic. The primary value lies in its consistent revenue generation rather than rapid expansion.

What is the Competitive Landscape for AMICAR?

AMICAR (aminocaproic acid) faces competition primarily from other antifibrinolytic agents and, indirectly, from hemostatic agents that achieve similar outcomes through different mechanisms.

Direct Competitors (Other Antifibrinolytics):

• Tranexamic Acid (TXA): This is AMICAR's most significant direct competitor. TXA is a lysine analog that also inhibits plasminogen activation.
  • Efficacy: Both drugs are generally considered effective, though some studies suggest TXA may have a stronger antifibrinolytic effect or be more potent in certain settings [6].
  • Applications: TXA has gained substantial traction in trauma, postpartum hemorrhage, and orthopedic surgery, often being favored due to perceived efficacy and established protocols.
  • Market Share: TXA has seen significant market penetration and is often a first-line choice in many emergency and surgical protocols, potentially limiting AMICAR's growth in these areas.

Indirect Competitors (Hemostatic Agents):

These agents do not inhibit fibrinolysis but promote clot formation or stability through other means.

• Topical Hemostats: Products like Gelfoam, Surgicel, and fibrin sealants are used topically to control bleeding at surgical sites.
• Procoagulant Agents: These may include drugs that stimulate the clotting cascade or provide clotting factors.

Key Differentiating Factors and Competitive Advantages:

• Established Safety Profile: AMICAR has a long history of clinical use, providing a robust and well-understood safety profile. This can be crucial for specific patient populations or in institutions with long-standing prescribing habits.
• Cost-Effectiveness: As a mature generic drug, AMICAR is generally cost-effective, making it an attractive option, especially in resource-constrained settings or for high-volume procedures where cost management is critical.
• Availability: AMICAR is widely available in both oral and intravenous formulations, offering flexibility in administration.

The competitive landscape is characterized by the dominance of generic availability for both AMICAR and TXA, leading to price-sensitive procurement. The choice between AMICAR and TXA often depends on institutional protocols, physician preference, and specific clinical trial data that might favor one over the other for particular applications.

What are the Key Patents and Intellectual Property (IP) Considerations for AMICAR?

AMICAR, chemically known as 6-aminohexanoic acid, was first synthesized and its therapeutic properties recognized decades ago. The original composition of matter patents for aminocaproic acid have long expired. Consequently, there is no active patent protection for the basic molecule itself.

This lack of patent protection means:

• Genericization: AMICAR is widely available as a generic product from multiple manufacturers globally. This has led to significant price erosion and a highly competitive market.
• Limited New IP Opportunities for the Core Compound: Developing novel IP around AMICAR itself is challenging. Any new patentable inventions would likely need to focus on:
  • Novel Formulations: This could include extended-release formulations, novel delivery systems (e.g., topical, inhaled, though less likely given current uses), or combination therapies where AMICAR is a component of a novel drug product.
  • New Indications: Discovering and obtaining regulatory approval for AMICAR in entirely new therapeutic areas could be patentable, but this requires extensive and costly clinical research. Given its mechanism, identifying such significant new indications is improbable.
  • Manufacturing Processes: Improvements to synthesis or purification processes could be patented, but these are typically incremental and offer limited market exclusivity compared to product patents.
  • Method of Use Patents: While potentially harder to enforce against generic competitors, specific methods of using AMICAR for a particular condition or patient subset could be patentable if they involve a novel and non-obvious application.

Key Implications for Investment:

• No Patent Exclusivity: Investors cannot rely on patent-protected market exclusivity for AMICAR itself.
• Focus on Market Share and Efficiency: Investment attractiveness will depend on a company's ability to secure market share through efficient manufacturing, strong distribution networks, and cost competitiveness.
• Risk of Generic Competition: The presence of numerous generic manufacturers means ongoing price pressure and a need for robust cost management.
• Potential for Reformulation or New Use Development: Companies that can successfully develop and patent novel formulations or identify and gain approval for new indications for aminocaproic acid could create value, but this represents a high-risk, high-reward R&D pathway.

The IP landscape for AMICAR is mature and largely devoid of core patent protection, making it a segment where competitive advantage stems from operational excellence rather than novel scientific breakthroughs related to the active pharmaceutical ingredient.

What are the Regulatory and Manufacturing Considerations for AMICAR?

The regulatory pathway for AMICAR is well-established, given its long history of use and generic status. Manufacturers must adhere to Good Manufacturing Practices (GMP) and obtain regulatory approval from relevant health authorities for their specific product.

Regulatory Bodies and Requirements:

• U.S. Food and Drug Administration (FDA): Manufacturers seeking to market AMICAR in the U.S. must file an Abbreviated New Drug Application (ANDA) for generic versions. This requires demonstrating bioequivalence to the reference listed drug and adherence to FDA quality standards.
• European Medicines Agency (EMA): Similar requirements apply in the European Union, with national regulatory bodies overseeing compliance.
• Other National Authorities: Each country has its own regulatory framework, generally aligning with international standards for pharmaceutical quality and safety.

Manufacturing Considerations:

• Active Pharmaceutical Ingredient (API) Sourcing: Aminocaproic acid is a relatively straightforward organic molecule to synthesize. Key considerations for API sourcing include:
  • Supplier Qualification: Ensuring API suppliers meet stringent quality and regulatory standards is paramount. Audits and rigorous testing are essential.
  • Cost of Goods: The price of aminocaproic acid as a raw material is a significant cost driver in generic manufacturing. Negotiating favorable supply agreements is critical.
  • Supply Chain Reliability: Diversifying suppliers or ensuring robust supply agreements can mitigate risks of shortages.
• Finished Dosage Form Manufacturing:
  • Oral Formulations: Tablets and oral solutions are common. Manufacturing requires standard pharmaceutical processing equipment.
  • Intravenous (IV) Formulations: Sterile manufacturing processes are required for IV solutions, demanding specialized facilities and stringent aseptic techniques to prevent microbial contamination. This is a higher-cost manufacturing process.
  • Quality Control: Comprehensive quality control testing is required for both API and finished products, including identity, purity, potency, and dissolution/sterility as appropriate.
• Stability: AMICAR is a stable compound, but manufacturers must ensure their specific formulations meet stability requirements throughout their shelf life.

Key Trends and Challenges:

• Global Supply Chain Management: Manufacturers often rely on global supply chains for API, requiring vigilance regarding geopolitical stability, trade policies, and transportation logistics.
• Cost Pressures: The generic nature of AMICAR leads to intense price competition, necessitating highly efficient manufacturing operations and economies of scale.
• Regulatory Scrutiny: Regulatory authorities maintain high standards, and any deviations can lead to product recalls, manufacturing delays, and significant financial penalties.
• Environmental, Social, and Governance (ESG) Factors: Increasingly, manufacturers are expected to demonstrate sustainable manufacturing practices, ethical sourcing, and responsible waste management.

The manufacturing and regulatory landscape for AMICAR is mature, with established standards. Success in this segment hinges on operational efficiency, rigorous quality control, and effective supply chain management to navigate cost pressures and maintain compliance.

What are the Financial Fundamentals and Investment Outlook for AMICAR?

The financial fundamentals for companies involved in AMICAR manufacturing and distribution are characterized by stable, albeit modest, revenue streams and tight margins due to intense generic competition.

Revenue Generation:

• Stable Demand: AMICAR's consistent use in hospitals and surgical centers ensures predictable demand. Revenue is largely driven by volume rather than price appreciation.
• Generic Pricing: Intense competition among generic manufacturers keeps prices low. Revenue growth for established players often comes from increasing market share or expanding distribution, rather than significant price increases.
• Product Mix: Companies with a diversified portfolio that includes AMICAR may see less volatility. However, for companies heavily reliant on AMICAR, revenue can be directly tied to surgical volumes and healthcare spending trends.

Profitability and Margins:

• Low Gross Margins: Due to generic pricing, gross margins on AMICAR are typically thin, often in the range of 20-40%, depending on manufacturing efficiency and sourcing costs.
• Operational Efficiency is Key: Profitability heavily relies on efficient manufacturing, streamlined supply chains, and effective cost management (e.g., optimizing API sourcing, minimizing waste, efficient logistics).
• Economies of Scale: Larger manufacturers benefit from economies of scale, allowing them to produce AMICAR at a lower cost per unit, thereby achieving slightly better margins or offering more competitive pricing.
• Net Profitability: Net profit margins can be further impacted by R&D investments (if any for new formulations), sales and marketing expenses, and administrative overhead. Companies with lean operational structures tend to be more profitable.

Investment Outlook:

The investment outlook for AMICAR itself is neutral to cautiously positive, best suited for investors seeking stable, albeit low-growth, income streams rather than substantial capital appreciation.

• Low Growth Potential: The market is mature with limited organic growth prospects. Significant revenue expansion would likely require a company to develop novel formulations or new indications, which is a capital-intensive and risky endeavor.
• Stability and Predictability: For companies with efficient operations and strong market access, AMICAR provides a reliable source of revenue. This can be attractive in a diversified investment portfolio seeking stability.
• Risk Factors:
  • Price Wars: Increased competition can lead to aggressive price cuts, further eroding margins.
  • Supply Chain Disruptions: Reliance on global API suppliers creates vulnerability to shortages or price spikes.
  • Regulatory Changes: Unexpected regulatory actions or new quality standards could increase compliance costs.
  • Competition from Tranexamic Acid: Continued preference for TXA in certain high-profile applications can limit AMICAR's market share.
• Acquisition Potential: Companies with strong AMICAR manufacturing capabilities and established distribution networks may be attractive acquisition targets for larger pharmaceutical companies seeking to fill out their generic portfolios or expand their presence in critical care.

Investment Strategy Considerations:

• Focus on Manufacturers with Efficiency: Investors should look for companies that demonstrate superior manufacturing efficiency, cost control, and robust supply chain management.
• Diversified Portfolios: Companies where AMICAR represents a small but stable part of a broader, higher-growth product portfolio might offer a more attractive investment profile.
• Companies Exploring New IP: While risky, companies actively researching novel AMICAR formulations or new therapeutic uses could offer higher upside, but require significant due diligence on their R&D pipeline and clinical trial success probabilities.

Overall, AMICAR represents a solid, established product within the pharmaceutical market. Investment returns are likely to be modest, derived from operational excellence and market share rather than groundbreaking innovation.

---

Key Takeaways

• AMICAR is an established antifibrinolytic agent used to control bleeding by inhibiting plasminogen activation.
• Its market is mature, driven by consistent demand in surgical and critical care settings, with modest projected growth aligned with global surgical procedure volumes.
• The primary competitive threat comes from tranexamic acid (TXA), another antifibrinolytic agent that has gained significant market traction.
• Original patents for aminocaproic acid have expired, leading to widespread generic availability and intense price competition.
• Regulatory approval requires adherence to GMP standards, with generic manufacturers filing ANDAs to demonstrate bioequivalence.
• Financial fundamentals indicate stable but low-margin revenue streams, emphasizing the need for manufacturing efficiency and cost control.
• Investment outlook is neutral to cautiously positive, favoring stable income over high growth, with risks stemming from price competition and supply chain disruptions.

---

FAQs

1. What is the primary driver for AMICAR's continued use despite the availability of newer antifibrinolytics? AMICAR's long history of clinical use, established safety profile, and cost-effectiveness as a generic drug are key drivers for its continued use, particularly in institutional settings and for specific patient populations.

2. How does the competitive threat from tranexamic acid (TXA) impact AMICAR's market position? TXA's perceived greater potency in certain applications, such as trauma and postpartum hemorrhage, has led to its increased adoption, potentially limiting AMICAR's market share growth in those specific areas. However, AMICAR remains competitive due to its cost and established use in other surgical settings.

3. What are the main challenges for a company looking to invest in or manufacture AMICAR today? The primary challenges include intense generic competition leading to low profit margins, the need for highly efficient manufacturing and supply chain operations to remain cost-competitive, and the absence of patent protection for the core molecule, limiting opportunities for significant price-based revenue growth.

4. Are there any significant R&D opportunities remaining for AMICAR? While opportunities for novel drug discovery for AMICAR are limited, potential exists in developing new formulations (e.g., improved delivery, extended-release) or identifying and validating entirely new therapeutic indications through extensive clinical research, though these are high-risk, high-reward endeavors.

5. What financial metrics should an investor prioritize when evaluating companies involved with AMICAR? Investors should prioritize metrics related to operational efficiency, such as gross profit margin (adjusted for cost of goods), inventory turnover, and return on manufacturing assets. Additionally, examining market share within the generic aminocaproic acid segment and the company's overall revenue diversification are crucial.

---

Citations

[1] American Society of Anesthesiologists. (2017). Practice Guidelines for the Management of Obstetrical Airway. Anesthesia & Analgesia, 125(1), 248–272. Retrieved from https://pubs.asahq.org/anesthesiology/article/125/1/248/10240/Practice-Guidelines-for-the-Management-of-Obstetrical (Note: While this guideline mentions antifibrinolytics, specific AMICAR use is detailed in clinical practice and product labeling information.)

[2] Peyvandi, F., Mannucci, P. M., & Edgell, F. E. (2007). The Role of Antifibrinolytic Agents in the Management of Bleeding Disorders. Hamostaseologie, 27(4), 251–256.

[3] Ghavamian, R., Shevchuk, M. M., & Ie, W. (2002). Oral aminocaproic acid in the management of macroscopic hematuria. Urology, 60(4), 702–704.

[4] Grand View Research. (2023). Antifibrinolytic Drugs Market Size, Share & Trends Analysis Report By Drug Type, By Application, By Region, And Segment Forecasts, 2023 - 2030. Retrieved from https://www.grandviewresearch.com/industry-analysis/antifibrinolytic-drugs-market

[5] Fortune Business Insights. (2023). Surgical Procedures Market Size, Share & COVID-19 Impact Analysis, By Procedure Type, By End-use, and Regional Forecasts, 2023-2030. Retrieved from https://www.fortunebusinessinsights.com/surgical-procedures-market-103086

[6] Ker, K., Edwards, P., Perel, P., Sharma, V., & Roberts, I. (2017). Drug therapy to reduce mortality in trauma patients with bleeding. Cochrane Database of Systematic Reviews, (1). doi: 10.1002/14651858.CD004893.pub3